Further studies are clearly needed to delineate the complexities of SPRY2 epigenetic regulation in CRC, especially in regard to the potential role of 5mC and 5hmC modifications of enhancer–promoter activity in SPRY2 expression. This evidence concerns the gene SPRY2 and colorectal carcinoma.